6. NCEP/Framingham risk scores: Estimate of 10-yr CHD risk in men without CHD
VBWG
Age (y) 20–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79
Points –9 –
Age (y) 20–39 40–49 50–59 60–69 70–79
Nonsmoker
Smoker
Points Total-C Age (y) (mg/dL) 20–39 40–49 50–59 60–69 70–79
<
160–
200–
240– ≥
Systolic BP Points (mm Hg) Untreated Treated
< – – – ≥
HDL-C (mg/dL) Points
≥60 –1 50– – <40 2
Point total: < >17 10-yr risk (%) < ≥30
Reilly MP, Rader DJ. Circulation. 2003;108:

7. ATP III update: LDL-C goals and cutpoints for treatment
VBWG
Risk category LDL-C goal Initiate TLC Consider drug therapy
High risk:
CHD or CHD risk <100 mg/dL ≥100 mg/dL ≥100 mg/dL equivalents*
(10-yr risk >20%)
Moderately high risk:
2+ risk factors <130 mg/dL ≥130 mg/dL ≥130 mg/dL
(10-yr risk 10%–20%)
Moderate risk‡:
2+ risk factors <130 mg/dL ≥130 mg/dL ≥160 mg/dL
(10-yr risk <10%)
Lower risk‡:
0–1 risk factors <160 mg/dL ≥160 mg/dL ≥190 mg/dL (160–189 mg/dL drugs optional)
(optional goal: <70 mg/dL)†
(<100 mg/dL; consider drug options)
(optional goal: <100 mg/dL)
(100–129 mg/dL; consider drug options)
*Diabetes or other noncoronary atherosclerotic disease
†Favored for very high-risk subset
‡No changes in moderate and lower-risk category
TLC = therapeutic lifestyle change
Grundy SM et al. Circulation. 2004;110: